135779-54-3

Upstream product

• 95-76-1 m,p-dichloroaniline 
• 31399-32-3 3-(3,4-dichlorophenylamino)propanoic acid 
• 104-94-9 4-methoxy-aniline 

Downstream Products

• 1548515-42-9 3-((3,4-dichlorophenyl)(4-fluorobenzyl)amino)-N-(4-methoxyphenyl)propanamide 
• 1548515-39-4 C₂₅H₂₀Cl₂F₆N₂O₂ 

Relevant academic research and scientific papers

Pharmacophore-based design, synthesis, and biological evaluation of novel 3-((3,4-dichlorophenyl)(4-substituted benzyl)amino) propanamides as cholesteryl ester transfer protein (CETP) inhibitors

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that plays an important role in decreasing high-density lipoprotein cholesterol (HDL-C) levels and increasing low-density lipoprotein cholesterol (LDL-C) levels. Inhibition of CETP may be a new therapy for treating atherosclerosis. Herein, we report the development of a ligand-based pharmacophore model and pharmacophore-based virtual screening of the ZINC/big-n-greasy database, leading to the identification of compound H-10 as a potential CETP inhibitor in vitro. Based on H-10, a series of 3-((3,4-dichlorophenyl)(4-substituted benzyl)amino) propanamides were designed, synthesized, and evaluated against CETP. Compound 4l was found to have the best activity, resulting in 85.0% inhibition of CETP at 10 μmol/L.